LLY Jan 2025 390.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

1.2100

0.0000

(0.00%)

As of 02:25PM EDT. Market open.

Loading interactive chart…

Investor's Business Daily
How A Top Fund Beats The Market By Owning Future Leaders
Julianne McHugh, lead manager of best mutual fund BNY Mellon Large Cap Securities, isn't interested in blue-chip stars of yesteryear.
Zacks
Zacks Investment Ideas feature highlights: Eaton, Eli Lilly and Arista Networks
Eaton, Eli Lilly and Arista Networks have been highlighted in this Investment Ideas article.
Reuters
UPDATE 2-India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says
Cipla is open to partnering with U.S. drugmaker Eli Lilly to market its blockbuster obesity treatment drugs in India, the company's CEO said on Friday. Global demand has outpaced supply for Lilly's Mounjaro and Zepbound as well as Danish rival Novo Nordisk's Wegovy and Ozempic. Sensing the market opportunity, Indian drugmakers, including Cipla, are working to develop their copycat versions of the weight-loss drugs to aggressively grab a larger share in the market in the world's most populous country.